These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36455667)

  • 1. Revisiting secondary prevention in coronary heart disease.
    Sigamani A; Gupta R
    Indian Heart J; 2022; 74(6):431-440. PubMed ID: 36455667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.
    Yusuf S; Islam S; Chow CK; Rangarajan S; Dagenais G; Diaz R; Gupta R; Kelishadi R; Iqbal R; Avezum A; Kruger A; Kutty R; Lanas F; Lisheng L; Wei L; Lopez-Jaramillo P; Oguz A; Rahman O; Swidan H; Yusoff K; Zatonski W; Rosengren A; Teo KK;
    Lancet; 2011 Oct; 378(9798):1231-43. PubMed ID: 21872920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-reported use of evidence-based medicine and smoking cessation 6 - 9 months after acute coronary syndrome: a single-centre perspective.
    Griffiths B; Lesosky M; Ntsekhe M
    S Afr Med J; 2014 Jun; 104(7):483-7. PubMed ID: 25214049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous coronary interventions for coronary artery disease: the long and short of optimizing medical therapy.
    Jaumdally R; Lip GY; Varma C
    Int J Clin Pract; 2005 Sep; 59(9):1070-81. PubMed ID: 16115184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary prevention of coronary heart disease in the elderly.
    Dornbrook-Lavender KA; Roth MT; Pieper JA
    Ann Pharmacother; 2003 Dec; 37(12):1867-76. PubMed ID: 14632542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
    El-Hajj MS; Saad A; Al-Suwaidi J; Al-Marridi WZ; Elkhalifa DH; Mohamed AA; Mahfoud ZR
    Curr Vasc Pharmacol; 2016; 14(4):394-403. PubMed ID: 26916397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The UK National Health Service: delivering equitable treatment across the spectrum of coronary disease.
    Hawkins NM; Scholes S; Bajekal M; Love H; O'Flaherty M; Raine R; Capewell S
    Circ Cardiovasc Qual Outcomes; 2013 Mar; 6(2):208-16. PubMed ID: 23481523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
    Høgh AL
    Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recommendations for secondary prevention of the clinical coronary cardiopathy].
    Rev Esp Cardiol; 1985; 38(1):14-20. PubMed ID: 2858911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Socioeconomic Factors, Secondary Prevention Medication, and Long-Term Survival After Coronary Artery Bypass Grafting: A Population-Based Cohort Study From the SWEDEHEART Registry.
    Nielsen SJ; Karlsson M; Björklund E; Martinsson A; Hansson EC; Malm CJ; Pivodic A; Jeppsson A
    J Am Heart Assoc; 2020 Mar; 9(5):e015491. PubMed ID: 32114890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Another treatment gap: restarting secondary prevention medications: the Women's Health Initiative.
    Robinson JG; Wallace R; Safford MM; Pettinger M; Cochrane B; Ko MG; O'Sullivan MJ; Masaki K; Petrovich H
    J Clin Lipidol; 2010; 4(1):36-45. PubMed ID: 20354566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of a randomized cluster trial to improve guideline-adherence of secondary preventive drugs prescription after coronary artery bypass grafting in China: Measurement and Improvement Studies of Surgical Coronary Revascularization: Secondary Prevention (MISSION-1) Study.
    Rao C; Du J; Li X; Li J; Zhang H; Zhao Y; Hu S; Jiang L; Zheng Z;
    Am Heart J; 2016 Aug; 178():9-18. PubMed ID: 27502847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directions.
    Lonn E; Grewal J
    Curr Vasc Pharmacol; 2006 Jul; 4(3):253-68. PubMed ID: 16842143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of preventive cardiovascular pharmacotherapy after coronary artery bypass graft surgery.
    Barry AR; Koshman SL; Norris CM; Ross DB; Pearson GJ
    Pharmacotherapy; 2014 May; 34(5):464-72. PubMed ID: 24877186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical Therapy Utilization and Long-Term Outcomes Following Percutaneous Coronary Intervention: Five-Year Results From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program.
    Xie JX; Gunzburger EC; Kaun L; Plomondon ME; Barón AE; Waldo SW; Virani SS; Maddox TM; Mavromatis K
    Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e005455. PubMed ID: 31665896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heartwatch: a secondary prevention programme in primary care in Ireland.
    Bennett K; Jennings S; Collins C; Boland M; Leahy J; Bedford D; Shelley E
    Eur J Cardiovasc Prev Rehabil; 2008 Dec; 15(6):651-6. PubMed ID: 19177599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial.
    Xavier D; Gupta R; Kamath D; Sigamani A; Devereaux PJ; George N; Joshi R; Pogue J; Pais P; Yusuf S
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):244-253. PubMed ID: 26857999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensity of Guideline-Directed Medical Therapy for Coronary Heart Disease and Ischemic Heart Failure Outcomes.
    Crosier R; Austin PC; Ko DT; Lawler PR; Stukel TA; Farkouh ME; Wang X; Spertus JA; Ross HJ; Lee DS
    Am J Med; 2021 May; 134(5):672-681.e4. PubMed ID: 33181105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of pharmacist-initiated interventions in improving acute coronary syndrome secondary prevention pharmacotherapy prescribing upon discharge.
    Hassan Y; Kassab Y; Abd Aziz N; Akram H; Ismail O
    J Clin Pharm Ther; 2013 Apr; 38(2):97-100. PubMed ID: 23441979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.